Background Subcutaneous Levetiracetam is increasingly used to control seizure activity in selected palliative patients. Despite this becoming a well-recognised approach quality evidence to support this remains sparse. This retrospective audit explores the use of subcutaneous Levetiracetam in palliative patients across the whole of the West Midlands, UK.

Methodology West Midland based Specialist Palliative Care Units (n=14) and Hospital Teams (n=17) were invited to participate in an electronic survey collecting anonymised retrospective data on patients in whom subcutaneous Levetiracetam had been used. Information gathered included; seizure aetiology and type, antiepileptic history, delivery of Levetiracetam, side effects and effectiveness.

Results Information generated from 31 cases demonstrated subcutaneous Levetiracetam use in a wide range of seizure aetiologies (space-occupying lesions (50%), pre-existing epilepsy, cerebrovascular disease, seizures secondary to Creutzfeldt-Jakob disease, leptomeningeal disease and Multiple Sclerosis). 48% patients had experienced seizure activity within the week prior to commencement on subcutaneous Levetiracetam and nearly all (93%) were already using antiepileptic drugs. Levetiracetam was delivered most commonly via a McKinley T34© continuous subcutaneous infusion (84%). The median dose of Levetiracetam on commencement was 1000 mg (range 250 mg – 3000 mg) and 12% of infusions were titrated over time due to seizure activity.

Levetiracetam was successfully mixed with Morphine, Midazolam, Metoclopramide and Dexamethasone. Concurrent Midazolam administration was used in 68% due to varying rationale. 81% reported no side effects attributable to Levetiracetam and 16% reported a local skin site reaction. No further seizures were documented in 70%, and 65% subcutaneous Levetiracetam continued until death.

Conclusions This study outlines current practice within the West Midlands, adds to the relatively small evidence base, will help inform the composition of regional guidelines and provide a platform upon which to develop future research.

171 STAFF PERCEPTIONS OF NON-PHARMACOLOGICAL INTERVENTIONS TO MANAGE DELIRIUM IN THE INPATIENT PALLIATIVE CARE SETTING

Claire Conway, Júliet Spiller, Emma Carduff, Anne Finucane. University of Edinburgh

Background and aim Delirium is a complex neuropsychiatric syndrome occurring in up to 88% of patients in palliative care inpatient settings in the weeks or hours preceding death. It is characterised by a disturbance in attention and awareness that develops over a short time and fluctuates in severity throughout the day. Management of a delirium episode includes the consideration of potentially treatable precipitating and aggravating factors followed by symptomatic treatment with drug therapy. A recent randomised clinical trial found no benefit of antipsychotic medication in the treatment of terminally ill patients, and called for an examination of the role of supportive interventions to treat delirium in palliative care settings.

Methods Semi-structured interviews were conducted with nine members of the medical and nursing inpatient teams across two Scottish hospices. Interviews were transcribed verbatim and analysed thematically.

Results Most participants employed a mix of pharmacological and non-pharmacological approaches to treat delirium at the end of life. Non-pharmacological strategies included i) reorientation, ii) modifying environmental factors, iii) familiar surroundings, iv) enabling and retaining autonomy, v) distraction from delirium, and vi) tactile stimulation.

Inadequate staffing was viewed as a barrier to the use of non-pharmacological interventions; whereas involving families in delirium management was viewed as helpful.

Conclusion A variety of non-pharmacological interventions were identified which were both commonly used and perceived to be effective by staff members in two palliative care inpatient units. An intervention study is now required to examine the effectiveness of supportive interventions to reduce delirium symptoms and severity in terminally ill patients, and to minimise delirium related distress in both the patient and their families.
This pilot suggests further study into the prevalence and management of glucocorticoids in patients with cancer, across all settings, would be beneficial to establish the need for formal guidelines.

**Method**

Systematic review with narrative synthesis designed and conducted according to the recommendations set out in Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Protocol (PRISMA-P) and PRISMA statements. Electronic databases, including MEDLINE, EMBASE, PsychINFO, Cochrane Library, Social Science Citation Index, OpenGrey and Grey Literature Report were searched, along with hand-searches, for studies using tools/criteria to identify potentially inappropriate prescribing in older people with dementia. Screening, extraction and quality assessment (Hawker score) were performed in duplicate.

**Results**

A total of 3,626 unique records were identified; 26 studies met the inclusion criteria (which included 26,534 participants, of which 21,285 (80%) had dementia or cognitive impairment). The mean participant age in these studies ranged from 72.5 to 86.8. The Hawker score ranged from 22/36 to 36/36, indicating all studies were fair to good quality. The Beer’s criteria was the most commonly used tool (15/26 studies). There were variations in how the tools were applied, with 13 out of 15 studies using the Beer’s criteria not using the full tool. Eight studies used more than one tool to identify potentially inappropriate prescribing. The prevalence of potentially inappropriate prescribing ranged from 14% to 74% in older people with dementia. The most commonly prescribed potentially inappropriate medications were benzodiazepines and anticholinergics.

**Conclusions**

Variations in tool application may partly explain variations in potentially inappropriate prescribing rates across studies. Recommendations include a more standardised tool usage, ensuring the tools comprehensively identify all potentially inappropriate medications and that the tools are kept up to date.

**Background**

Seizures are common in the palliative care population. For patients who are unable to take oral medication, seizure management can become problematic but there is little consensus on best practice, particularly for patients with longer prognoses.

**Aim**

To examine prescribing of non-oral and ‘as required’ anticonvulsant medication across multiple palliative settings (community/hospice/acute hospital).

**Method**

A regional multi-centre audit of prescribing practice was conducted from October to December 2017. Inclusion criteria: adult patients requiring anticonvulsant medication but unable to take oral preparations. Practice was assessed against the full tool. Eight studies used more than one tool to identify potentially inappropriate prescribing. The prevalence of potentially inappropriate prescribing ranged from 14% to 74% in older people with dementia. The most commonly prescribed potentially inappropriate medications were benzodiazepines and anticholinergics.

**Results**

When unable to take oral medications, 25 patients (96%) commenced a continuous subcutaneous infusion (CSCI). Fourteen patients were prescribed levetiracetam (250 mg-3 g/24 hours), seven were prescribed midazolam (15–30 mg/24 hours), two were prescribed sodium valproate (600 mg/24 hours) and two were prescribed combination levetiracetam (3 g) and midazolam (30–40 mg). One patient had no regular